Pratapneni A, Klebaner D, Soltys S, Rahimy E, Gibbs I, Chang S
BMC Cancer. 2025; 25(1):323.
PMID: 39984889
PMC: 11846292.
DOI: 10.1186/s12885-025-13655-6.
Ciurlia E, Santo B, Barba M, Cavalera E, De Franco P, De Matteis S
Front Oncol. 2025; 14:1525926.
PMID: 39896186
PMC: 11782232.
DOI: 10.3389/fonc.2024.1525926.
Luo W, Clair W
Int J Mol Sci. 2024; 25(23).
PMID: 39684602
PMC: 11641765.
DOI: 10.3390/ijms252312891.
Yoo G, Sung S, Song J, Kim B, Kwak Y, Kim K
Radiat Oncol J. 2024; 42(3):171-180.
PMID: 39354820
PMC: 11467485.
DOI: 10.3857/roj.2023.01046.
Romero Fernandez J, Cordoba Largo S, Benlloch Rodriguez R, Gil Haro B
Cancers (Basel). 2024; 16(16).
PMID: 39199577
PMC: 11352652.
DOI: 10.3390/cancers16162804.
Dose Rate Effects from the 1950s through to the Era of FLASH.
Held K, McNamara A, Daartz J, Bhagwat M, Rothwell B, Schuemann J
Radiat Res. 2024; 202(2):161-176.
PMID: 38954556
PMC: 11426361.
DOI: 10.1667/RADE-24-00024.1.
Escalated-dose radiotherapy for unresected locally advanced pancreatic cancer: Patterns of care and survival in the United States.
Shi C, De B, Tran Cao H, Liu S, Florez M, Kouzy R
Cancer Med. 2024; 13(12):e7434.
PMID: 38923407
PMC: 11200087.
DOI: 10.1002/cam4.7434.
Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors.
Wu Y, Yi M, Niu M, Zhou B, Mei Q, Wu K
Cancer Commun (Lond). 2024; 44(7):739-760.
PMID: 38837878
PMC: 11260771.
DOI: 10.1002/cac2.12576.
How Does the Number of Brain Metastases Correlate With Normal Brain Exposure in Single-Isocenter Multitarget Multifraction Stereotactic Radiosurgery.
Zheng D, Yoon J, Jung H, Lemus O, Gou L, Zhou Y
Adv Radiat Oncol. 2024; 9(6):101499.
PMID: 38681891
PMC: 11047183.
DOI: 10.1016/j.adro.2024.101499.
An in-silico planning study of stereotactic body radiation therapy for polymetastatic patients with more than ten extra-cranial lesions.
Iori F, Torelli N, Unkelbach J, Tanadini-Lang S, Christ S, Guckenberger M
Phys Imaging Radiat Oncol. 2024; 30:100567.
PMID: 38516028
PMC: 10950805.
DOI: 10.1016/j.phro.2024.100567.
The dosimetric parameters impact on local recurrence in stereotactic radiotherapy for brain metastases.
Berthet C, Lucia F, Bourbonne V, Schick U, Lecouillard I, Le Deroff C
Br J Radiol. 2024; 97(1156):820-827.
PMID: 38377402
PMC: 11025672.
DOI: 10.1093/bjr/tqae029.
Radiotherapy in Preclinical Models of Brain Metastases: A Review and Recommendations for Future Studies.
Shi W, Tanzhu G, Chen L, Ning J, Wang H, Xiao G
Int J Biol Sci. 2024; 20(2):765-783.
PMID: 38169621
PMC: 10758094.
DOI: 10.7150/ijbs.91295.
Radiosurgery for Brain Metastases: Challenges in Imaging Interpretation after Treatment.
Romano A, Moltoni G, Blandino A, Palizzi S, Romano A, de Rosa G
Cancers (Basel). 2023; 15(20).
PMID: 37894459
PMC: 10605307.
DOI: 10.3390/cancers15205092.
Radiobiological Meta-Analysis of the Response of Prostate Cancer to Different Fractionations: Evaluation of the Linear-Quadratic Response at Large Doses and the Effect of Risk and ADT.
Pardo-Montero J, Gonzalez-Crespo I, Gomez-Caamano A, Gago-Arias A
Cancers (Basel). 2023; 15(14).
PMID: 37509320
PMC: 10377316.
DOI: 10.3390/cancers15143659.
Mathematical model combined with microdosimetric kinetic model for tumor volume calculation in stereotactic body radiation therapy.
Nakano H, Shiinoki T, Tanabe S, Utsunomiya S, Takizawa T, Kaidu M
Sci Rep. 2023; 13(1):10981.
PMID: 37414844
PMC: 10326039.
DOI: 10.1038/s41598-023-38232-4.
Hypofractionated Radiotherapy in Localized, Low-Intermediate-Risk Prostate Cancer: Current and Future Prospectives.
Lo Greco M, Marletta G, Marano G, Fazio A, Buffettino E, Iudica A
Medicina (Kaunas). 2023; 59(6).
PMID: 37374348
PMC: 10301277.
DOI: 10.3390/medicina59061144.
Accumulation of sublethal radiation damage and its effect on cell survival.
Vassiliev O
Phys Med Biol. 2022; 68(1).
PMID: 36533628
PMC: 9855632.
DOI: 10.1088/1361-6560/aca5e7.
The "Combo" radiotherapy treatment for high-risk grade 2 meningiomas: dose escalation and initial safety and efficacy analysis.
Pontoriero A, Critelli P, Conti A, Cardali S, Angileri F, Germano A
J Neurooncol. 2022; 161(2):203-214.
PMID: 35927392
DOI: 10.1007/s11060-022-04107-3.
Towards personalised dosimetry in patients with liver malignancy treated with Y-SIRT using in vivo-driven radiobiological parameters.
Gholami Y, Willowson K, Bailey D
EJNMMI Phys. 2022; 9(1):49.
PMID: 35907097
PMC: 9339072.
DOI: 10.1186/s40658-022-00479-7.
Evaluation of Biological Effective Dose in Gamma Knife Staged Stereotactic Radiosurgery for Large Brain Metastases.
Cui T, Weiner J, Danish S, Chundury A, Ohri N, Yue N
Front Oncol. 2022; 12:892139.
PMID: 35847934
PMC: 9280470.
DOI: 10.3389/fonc.2022.892139.